New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
复制标题
DOI：
--
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
P. Therasse;S. Arbuck;E. Eisenhauer;J. Wanders;R. Kaplan;L. Rubinstein;J. Verweij;M. V. Van Glabbeke-M.-V.-Van-G
中科院分区：
文献类型：
--
作者：
P. Therasse;S. Arbuck;E. Eisenhauer;J. Wanders;R. Kaplan;L. Rubinstein;J. Verweij;M. V. Van Glabbeke-M.-V.-Van-G
抗癌细胞毒性剂的抗肿瘤活性（基于它们可以产生的肿瘤缩小量）经过了一个研究过程。 20 世纪 70 年代末，国际抗癌联盟和世界卫生组织引入了肿瘤反应评估的具体标准。 1994年，几个参与临床研究的组织联合起来，根据此后获得的经验和知识，对这些标准进行了审查。经过几年的深入讨论，一套新的指导方针已经准备就绪，将取代以前的标准。与此同时，其中一个参与小组开发了一种模型，通过该模型可以从肿瘤病变的一维测量而不是通常的二维方法中得出反应率。这一新概念已在很大程度上得到实体瘤组疗效评估标准的验证，并已纳入现有指南。这篇特别文章还提供了一些哲学背景来阐明响应评估的各种目的。它提出了一种模型，通过对所有现有病变（以目标病变（待测量）和非目标病变为特征）进行综合评估，用于推断对治疗的总体反应。评估肿瘤病变的方法得到了更好的编纂，在指南中进行了简要说明，在附录 I 中进行了更详细的说明。反应评估的所有其他方面都已在适当的时候进行了讨论、审查和修改。
Anticancer cytotoxic agents go through a process by which their antitumor activity-on the basis of the amount of tumor shrinkage they could generate-has been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical research combined forces to tackle the review of these criteria on the basis of the experience and knowledge acquired since then. After several years of intensive discussions, a new set of guidelines is ready that will supersede the former criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. This special article also provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate.